![]( "Nektar Therapeutics (NASDAQ: NKTR)")
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Nektar Therapeutics (NASDAQ: NKTR), Biospecifics Technologies Corp (NASDAQ: BSTC) and Xoma Corp (NASDAQ: XOMA) with bullish sentiments.
Nektar Therapeutics (NASDAQ: NKTR)
In a report released today, Debjit Chattopadhyay from H.C. Wainwright maintained a Buy rating on Nektar Therapeutics (NASDAQ: NKTR), with a price target of $125. The company’s shares closed on Friday at $83.66.
According to TipRanks.com, Chattopadhyay is a 3-star analyst with an average return of 2.0% and a 49.4% success rate. Chattopadhyay covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Mersana Therapeutics Inc, and Jounce Therapeutics Inc.
Currently, the analyst consensus on Nektar Therapeutics is Strong Buy and the average price target is $107.63, representing a 28.7% upside.
In a report issued on April 20, Seaport Global also initiated coverage with a Buy rating on the stock with a $120 price target.
See today’s analyst top recommended stocks >>
Biospecifics Technologies Corp (NASDAQ: BSTC)
In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Biospecifics Technologies Corp (NASDAQ: BSTC), with a price target of $65. The company’s shares closed on Friday at $42.73.
According to TipRanks.com, Selvaraju is ranked 0 out of 5 stars with an average return of -7.4% and a 35.5% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as IntelliPharmaCeutics International, EyePoint Pharmaceuticals Inc, and Synergy Pharmaceuticals Inc.
Biospecifics Technologies Corp has an analyst consensus of Moderate Buy, with a price target consensus of $65.
Xoma Corp (NASDAQ: XOMA)
H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Xoma Corp (NASDAQ: XOMA) today and set a price target of $49. The company’s shares closed on Friday at $24.37.
According to TipRanks.com, Pantginis is ranked 0 out of 5 stars with an average return of -14.5% and a 32.7% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group Inc, Applied Genetic Technologies, and Iovance Biotherapeutics Inc.
Xoma Corp has an analyst consensus of Moderate Buy, with a price target consensus of $41.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
